Previous 10 | Next 10 |
2024-03-12 05:14:45 ET More on related stocks: Vail Resorts, Inc. (MTN) Q2 2024 Earnings Call Transcript Oracle Corporation (ORCL) Q3 2024 Earnings Call Transcript Bilibili Stock Downgraded To Sell After Assessing Q4 Earnings Oracle in charts: Cloud services ...
2024-03-11 16:36:54 ET More on Acadia Pharma Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing Acadia Pharmaceuticals: Daybue Growth Concerns, Important Data Readout Coming ACADIA Pharmaceuticals Inc. (ACAD) Q4 2023 Earnings Call Transcript ...
- Study Did Not Meet Primary Endpoint Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significan...
2024-03-10 08:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44 th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time. A live webcast of Acadia’s presentation will be accessible on the company’...
- 2023 total net product sales of $726.4 million, reflecting 40% revenue growth. - Fourth quarter DAYBUE ™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million. - Fourth quarter NUPLAZID ® (pimavanserin) net pr...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-18 01:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Company to host conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, after the close of the U...
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
NASDAQ Market:
ACADIA Pharmaceuticals Inc. Website:
— Video series created by Rett caregiver and award-winning TV producer, AJ Tesler, and family, showcases the adapted adventures of families living with Rett syndrome — Documentary series to be showcased on Rett Revealed, a website designed to explain and highlight life with ...
2024-05-08 22:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- First quarter NUPLAZID ® (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE ™ (trofinetide) net product sales of $75.9 million Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ende...